The ATM or CHK2 mutant cell lines typically also did not show sensitivity to DNA damaging agents and PARP inhibitors, and despite promising earlier results, olaparib did not lead to improved overall survival for patients with ATM-negative gastric tumors in a phase 3 trial [49, 50]. Here, CHEK2 is linked to gastric neoplasm.